TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on Tuesday, February 24, 2026, at 11:00 A.M. (Toronto Time) at Gardiner Roberts LLP, Bay Adelaide Centre, East Tower, 22 Adelaide Street West, Suite 3600, Toronto, Ontario, M5H 4E3 (the “Meeting”). A total of 83,756,898 Common Shares of the Corporation (“Common Shares”) representing 49.27% of ...

Core Viewpoint - Labrador Gold Corp. has received a recommendation from Institutional Shareholder Services Inc. (ISS) for shareholders to vote exclusively on the BLUE Proxy in support of the company's resolutions during the upcoming Annual General and Special Meeting on February 24, 2026 [1][7]. Group 1: Proxy Voting Recommendations - ISS advises shareholders to vote "FOR" all of LabGold's resolutions and "AGAINST"/"WITHHOLD" on the resolutions proposed by the Dissident, Coloured Ties Capital Inc. [1][3] - The deadline for shareholders to submit their votes on the BLUE Proxy is February 20, 2026, at 11:00 a.m. (Toronto time) [16]. Group 2: ISS's Analysis of the Dissident's Case - ISS concluded that the Dissident has not presented a compelling case for change, noting that criticisms regarding the sale of Kingsway and NFG shares rely on hindsight assumptions about metals prices [4]. - The Dissident's campaign lacks essential elements of thoughtful activism, such as a clear plan and qualifications for management nominees [4]. Group 3: Support for LabGold's Strategy - ISS supports LabGold's hybrid mining/investment model, which allows for continued exploration and diversification through minority positions [5]. - The proposed change of business is seen as a better path forward compared to the status quo, despite inherent risks [5]. Group 4: Company Overview and Projects - Labrador Gold Corp. is focused on acquiring and exploring gold projects in Eastern Canada, with significant potential in critical minerals [12]. - The Watson Project, a joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt, which is underexplored compared to other regions [13]. - The Hopedale property and Borden Lake project also show potential for gold and other minerals, with ongoing exploration efforts identifying various anomalies [14][15].

Material Deficiencies in the Dissident’s Gold Proxy Have Been Identified by LabGoldThe Dissident’s Failure to Adhere to its Own Requisition May Affect the Validity of Their Gold ProxyShareholders are Urged to Vote ONLY on the BLUE Proxy or BLUE VIF to Ensure Votes Are Counted, and to Disregard any Gold or Other Proxy That They Receive From the Dissident Questions? Need Help Voting BLUE? Contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), email contactus@kingsdaleadvisors.com, or visit ...

Core Insights - Illumina, Inc. announced preliminary financial results for Q4 and fiscal year 2025 ahead of the J.P. Morgan Healthcare Conference [1] Preliminary Fourth Quarter 2025 Results - Revenue for Q4 2025 is approximately $1.155 billion, representing a 5% increase from Q4 2024 (4% increase on a constant currency basis) [7] - Ex-China revenue for Q4 2025 is approximately $1.100 billion, up 7% from Q4 2024 [7] - GAAP diluted EPS is projected to be between $2.14 and $2.17, while non-GAAP diluted EPS is expected to be between $1.27 and $1.30 [7] Preliminary Fiscal Year 2025 Results - Total revenue for fiscal year 2025 is approximately $4.34 billion, flat compared to 2024 (constant currency basis) [7] - Ex-China revenue for fiscal year 2025 is approximately $4.10 billion, up 2% from 2024 [7] - GAAP diluted EPS for the fiscal year is projected to be between $5.42 and $5.45, while non-GAAP diluted EPS is expected to be between $4.76 and $4.79 [7] Non-GAAP Financial Measures - The company reports non-GAAP results to provide a clearer view of operating performance, excluding certain charges such as amortization of acquired intangible assets and other adjustments [3][4] - Non-GAAP diluted EPS is a key metric used by the board of directors to assess management performance and compensation [3][14] Forward-Looking Guidance - The company provides forward-looking guidance on a non-GAAP basis, including revenue growth rates, but cannot reconcile these to GAAP measures due to uncertainties [5][6] About Illumina - Illumina focuses on improving human health through genomic technologies, serving various markets including life sciences, oncology, and agriculture [9]

Funding and Investment - Alamar Biosciences, Inc. closed an oversubscribed convertible notes financing, raising over $50 million in new capital, with participation from new investors T. Rowe Price Investment Management, Inc. and Braidwell LP, alongside existing investors like Illumina Ventures and Sands Capital [1][2] - The financing will support the commercial advancement of Alamar's precision proteomics platform, aimed at enhancing early disease detection [1][2] Leadership and Board Expansion - Dr. Stephen Williams has been appointed as Chief Scientific Officer, bringing over 30 years of experience in precision medicine and biomarker innovation [7] - Rebecca Chambers and Dr. Frank Witney have been appointed to the board of directors, contributing extensive financial and life sciences leadership experience [8][9] - The leadership team expansion is intended to support Alamar's growth and commitment to operational excellence [6][9] Company Overview - Alamar Biosciences is focused on precision proteomics to enable early disease detection, utilizing proprietary NULISA™ technology and the ARGO™ HT System for ultra-high sensitivity [12]

Core Insights - Heartbeam Inc's shares increased significantly by 43.3% to $0.86 in pre-market trading following the announcement of its regulatory strategy after the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software [1][2] Company Developments - Heartbeam is exploring multiple regulatory options, including an appeal process or a 510(k) resubmission to demonstrate that its device is equivalent to legally marketed products [1] Market Movements - Other notable pre-market stock movements include: - SMX PLC surged 73.1% to $30.12 after a previous jump of 194% [6] - Zenta Group Co Ltd gained 26.7% to $3.18 [6] - Waton Financial Ltd rose 21.1% to $3.74 [6] - Verrica Pharmaceuticals Inc increased by 9.7% to $7.36 after announcing a $50 million private placement [6] - Conversely, several companies experienced declines, such as: - FBS Global Ltd fell 24.3% to $0.51 [6] - Tilray Brands Inc declined 15% to $0.88 following a reverse stock split announcement [6] - Solo Brands Inc dipped 14.4% to $7.19 after reporting disappointing third-quarter results [6]

Core Insights - Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a quiet news cycle [1] Company Summaries - Modular Medical, Inc. (MODD) shares increased by 11.51% to $0.4380 after a previous decline of 1.80% at the close, following the IRB approval for its Pivot insulin delivery system study announced on November 17 [2] - Standard BioTools Inc. (LAB) saw a 4.90% rise to $1.50 after a 0.70% gain during regular trading, following a strategic collaboration with Molecular Instruments announced on November 19 [3] - Werewolf Therapeutics, Inc. (HOWL) rose 4.39% to $1.0199 after a strong 7.33% gain during regular trading, reflecting continued investor optimism despite no new updates [4] - Cogent Biosciences, Inc. (COGT) climbed 6.09% to $42.85 in after-hours trading, building on a 1.69% rise during regular trading, indicating strong investor confidence in its pipeline [5] - Longeveron Inc. (LGVN) shares increased by 4.59% to $0.6772, extending gains from a 7.02% rise during regular trading, with upcoming presentation of Alzheimer's study results at CTAD 2025 highlighting ongoing research [6] - AbCellera Biologics Inc. (ABCL) gained 3.85% to $3.78 after a 0.55% increase during regular trading, reflecting renewed investor interest in its antibody discovery platform [7]

Core Insights - Gorilla Technology Group Inc. reported a significant increase in third-quarter revenue, reaching $26.5 million, which represents a 32% year-over-year growth attributed to advancements in AI infrastructure and various projects across multiple regions [2]. Financial Performance - The company achieved breakeven earnings per share, or 26 cents per share on an adjusted basis [2]. - Following the financial results announcement, shares of Gorilla Technology Group rose by 13.7%, reaching $14.35 in pre-market trading [2].

Core Insights - Several small-cap healthcare and biotech companies experienced significant price increases in after-hours trading following earnings updates or upcoming financial disclosures [1] Company Summaries - MacroGenics, Inc. (MGNX) saw a 10.2% rise to $1.62 after hours, recovering from a 3.29% decline during the regular session. The company reported a third-quarter net income of $16.8 million, or $0.27 per share, down from $56.3 million, or $0.90 per share, year-over-year. Revenue fell to $72.8 million from $110.7 million [2] - SELLAS Life Sciences Group, Inc. (SLS) advanced 9.4% to $1.63 in after-hours trading. The company narrowed its quarterly net loss to $6.8 million, or $0.06 per share, compared to $7.1 million, or $0.10 per share, in the prior-year quarter. As of September 30, 2025, SELLAS reported cash and equivalents of approximately $44.3 million [3] - Standard BioTools Inc. (LAB) increased by 4.24% to $1.23 after hours, despite no official press releases or updates on Wednesday. The stock had closed slightly lower during the regular session [4] - KORU Medical Systems, Inc. (KRMD) gained 8.47% to $4.10 after hours, following a 1.34% increase earlier in the day. The company reported a narrower net loss of $0.8 million for the third quarter, compared to $1.6 million in the prior-year period. Revenue rose 27.2% to $10.4 million. KORU also raised its full-year revenue guidance to a range of $40.5 million - $41.0 million and reaffirmed its gross margin outlook of 61%-63% [5] - Hyperfine, Inc. (HYPR) climbed 8.18% to $1.19 after hours. No new announcements were made on Wednesday, but the company is scheduled to release its third-quarter results on Thursday, with analysts anticipating a loss of $0.10 per share and revenue of $3.52 million [6] - Wave Life Sciences Ltd. (WVE) added 5.68% to reach $7.35 in after-hours trading. The company reported a third-quarter net loss of $53.9 million, an improvement from $61.8 million in the prior-year quarter. Revenue for the period was $7.6 million, compared to a negative revenue figure of ($7.7) million last year [7]

Core Insights - Illumina Protein Prep is revolutionizing proteomics by providing the broadest coverage of the blood proteome at the lowest cost per protein target, processing over 40,000 samples globally [1][2] - The solution enhances genomic studies with exceptional specificity, sensitivity, and precision, facilitating breakthroughs in various diseases [2][3] - Collaborations with institutions like Genomics England and PRECISE-SG100K are demonstrating the potential of proteomics in advancing research and clinical applications [6][9] Group 1: Product Launch and Impact - Illumina Protein Prep launched globally in September, enabling researchers to process a significant number of samples and generate comprehensive omic data [1] - The Sydney Mass Spectrometry facility is the first in the Asia Pacific region to adopt this technology, successfully conducting experiments that revealed significant biological insights [4][5] - The solution serves as an alternative or complement to mass spectrometry, enhancing researchers' ability to derive transformative insights [3] Group 2: Research Collaborations and Findings - Genomics England's use of Illumina Protein Prep in its 100,000 Genomes Project resulted in a 7.5% increase in disease classification when integrating genomics and proteomics [6] - The PRECISE-SG100K study aims to analyze 10,000 plasma samples to develop a standardized dataset for therapeutic target interrogation [9][10] - These studies highlight the importance of proteomics in understanding disease mechanisms, particularly in underrepresented populations [8] Group 3: Future Directions and Innovations - Illumina is committed to advancing proteomics through AI-driven infrastructure, integrating secondary and tertiary analysis in a single workflow [2] - The company plans to benchmark existing clinical mass spectrometry studies with Illumina Protein Prep to further validate its capabilities [5] - Ongoing collaborations and studies are expected to enhance the quality and depth of insights into genetic variants and protein expression, contributing to drug discovery [8]